Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 9:13:677.
doi: 10.12688/f1000research.150931.2. eCollection 2024.

Tourette syndrome research highlights from 2023

Andreas Hartmann  1 , Per Andrén  2 , Cyril Atkinson-Clement  3 , Virginie Czernecki  1 , Cécile Delorme  1 , Nanette Mol Debes  4 , Simon Morand-Beaulieu  5 , Kirsten Müller-Vahl  6 , Peristera Paschou  7 , Natalia Szejko  8 , Apostolia Topaloudi  7 , Kevin J Black  9
Affiliations
Review

Tourette syndrome research highlights from 2023

Andreas Hartmann et al. F1000Res. .

Abstract

In this, the tenth annual update for the F1000Research Tics collection, we summarize research reports from 2023 on Gilles de la Tourette syndrome and other tic disorders. The authors welcome article suggestions and thoughtful feedback from readers.

Keywords: Tics; Tourette; annual review.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AH is a consultant for Noema Pharma. PA has received royalties from the Tourette OCD Alberta Network. CD is a consultant for Medtronic. NMD has no conflicts of interest. VC has no conflict of interest. KU participated in a clinical trial sponsored by Emalex Biosciences. PP has no conflict of interest. AT has no conflict of interest. CAC has no conflict of interest. NSZ participated in clinical trial supported by Emalex and Nuvelution. She received scientific grants from the Polish Neurological Society, European Stroke Organisation, Polish Ministry of Health, Polish Foundation of Science, Tourette Association of America, American Academy of Neurology and American Brain Foundation. She received speaker honoraria from Biogen. PP was supported by EMTICS (Grant No. 278367), TS-EUROTRAIN (Grant No. 316978), the National Institute of Neurological Disorders and Stroke (Grant No. R01NS105746), U.S. National Science Foundation (Grant Nos. 2006929 and 1715202), and the National Institute of Mental Health (Grant No. R01MH126213). KMV has received financial or material research support from EU (FP7-HEALTH-2011 No. 278367, FP7-PEOPLE-2012-ITN No. 316978), DFG: GZ MU 1527/3-1 and GZ MU 1527/3-2, BMBF: 01KG1421, National Institute of Mental Health (NIMH), Tourette Gesellschaft Deutschland e.V., Else-Kröner-Fresenius-Stiftung, GW pharmaceuticals, Almirall, Abide Therapeutics, Emalex Biosciences, Inc., Noema Pharma, CannaXan, and Therapix Biosiences. She has received consultant's and other honoraria from Abide Therapeutics, adjupharm, Alexion, AMP Alternative Medical Products GmbH, Ingelheim International GmbH, Bionorica Ethics GmbH, CannaMedical Pharma GmbH, Canopy Grouth, Columbia Care, CTC Communications Corp., Demecan, Enua pharma, Ethypharm GmbH, Eurox Group, Global Praxis Group Limited, Hormosan Pharma GmbH, Lundbeck, MCI Germany, Neuraxpharm, Noema Pharma, Sanity Group, Stadapharm GmbH, Synendos Therapeutics AG, Syqe, Tilray, and Zambon. She is an advisory/scientific board member for Alexion, Branchenverband Cannabiswirtschaft e.V. (BvCW), CannaMedical Pharma GmbH, Bionorica Ethics GmbH, CannaXan GmbH, Canopy Growth, Columbia Care, Ethypharm GmbH, Hormosan Pharma GmbH, IMC Germany, Leafly Deutschland GmbH, Neuraxpharm, Sanity Group, Stadapharm GmbH, Synendos Therapeutics AG, Syqe Medical Ltd., Therapix Biosciences Ltd., and Tilray. She has received speakers fees from Agaplesion Frankfurter Diakonie Kliniken gemeinnützige GmbH, Almirall, Aphria Deutschland GmbH, Arbeitsgemeinschaft Cannabis als Medizin (ACM), Bedrocan, Branchenverband Cannabiswirtschaft e.V. (BvCW), Camurus, CEREBRO SPAIN BIDCO S.L, Cogitando GmbH, Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN), Diplomado Internacional de Endocannabinología (Programa Universitario de Investigación en Salud - PUIS, UNAM), Dresden International University (DIU), Emalex, Eurox Deutschland GmbH, Ever pharma GmbH, Georgia Medical Cannabis Project (GMCP), GROW, Hessische Landesstelle für Suchtfragen e.V. (HLS), LIO Pharmaceuticals GmbH, Medizinischer Dienst Westfalen Lippe, Meinhardt Congress GmbH, PR Berater, Spectrum Therapeutics GmbH, Swiss Alpinopharm, targoEvent GmbH, Takeda GmbH, Tilray, von Mende Marketing GmbH, and Wayland Group. She has received royalties from Deutsches Ärzteblatt, Der Neurologie und Psychiater, Elsevier, Medizinisch Wissenschaftliche Verlagsgesellschaft Berlin, and Kohlhammer. She served as a guest editor for Frontiers in Neurology on the research topic "The neurobiology and genetics of Gilles de la Tourette syndrome: new avenues through large-scale collaborative projects", is an associate editor for "Cannabis and Cannabinoid Research", an Editorial Board Member of "Medical Cannabis and Cannabinoids" and "MDPI-Reports" and a scientific board member for "Zeitschrift für Allgemeinmedizin". SMB was supported by the Clinical Research Training Scholarship in Tourette syndrome from the Tourette Association of America and the American Brain Foundation, in collaboration with the American Academy of Neurology. PA has received funding from Region Skåne, The Crafoord Foundation, L.J. Boëthius Stiftelse, Stiftelsen Lindhaga, The Söderström Königska Foundation, Fredrik och Ingrid Thurings stiftelse, and The Sven Jerring Foundation outside the submitted work. KJB participated in a clinical trial sponsored by Emalex Biosciences and was an unpaid consultant for Noema Pharma AG; he received research support from Zhittya Genesis Medicine and from NIH (R01MH118217, UL1TR002345, R01MH126213, R21NS133875).

Figures

Figure 1.
Figure 1.. Publications on Tourette syndrome, by year (PubMed).
One third of these (2 669) have appeared in the past 10 years.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Abbasi P, Tanhaie S, Kazeminia M: Prevalence of depression and anxiety in patients with Tourette syndrome; 1997 to 2022: a systematic review and meta-analysis. Ital. J. Pediatr. 2023;49:160. 10.1186/s13052-023-01562-0 - DOI - PMC - PubMed
    1. Abelson JF, Kwan KY, O’Roak BJ, et al. : Sequence variants in SLITRK1 are associated with Tourette’s syndrome. Science. 2005;310:317–320. 10.1126/science.1116502 - DOI - PubMed
    1. Albin RL, Minderovic C, Koeppe RA: Normal striatal vesicular acetylcholine transporter expression in Tourette Syndrome. eNeuro. 2017 Jul-Aug;4(4): ENEURO.0178-17.2017. 10.1523/ENEURO.0178-17.2017 - DOI - PMC - PubMed
    1. Andersen K, Groth C, Skov L, et al. : Childhood Comorbidity Severity Impacts Adolescent Substance Consumption in Patients With Tourette Syndrome. Pediatr. Neurol. 2023a;145:88–93. 10.1016/j.pediatrneurol.2023.05.004 - DOI - PubMed
    1. Andersen K, Jensen I, Okkels KB, et al. : Clarifying the Differences between Patients with Organic Tics and Functional Tic-Like Behaviors. Healthcare (Basel). 2023b;11:11. 10.3390/healthcare11101481 - DOI - PMC - PubMed

LinkOut - more resources